
The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children. Intuniv (guanfacine hydrochloride prolonged …

Shire has posted strong growth in its full-year results, showing that the company is faring well even after the collapse …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

